Cargando…
CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432308/ https://www.ncbi.nlm.nih.gov/pubmed/37600998 http://dx.doi.org/10.21037/hbsn-23-247 |
| _version_ | 1785091373856194560 |
|---|---|
| author | Wang, Yinhan Xu, Haifeng |
| author_facet | Wang, Yinhan Xu, Haifeng |
| author_sort | Wang, Yinhan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10432308 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104323082023-08-18 CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease Wang, Yinhan Xu, Haifeng Hepatobiliary Surg Nutr Editorial Commentary AME Publishing Company 2023-07-06 2023-08-01 /pmc/articles/PMC10432308/ /pubmed/37600998 http://dx.doi.org/10.21037/hbsn-23-247 Text en 2023 Hepatobiliary Surgery and Nutrition. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Wang, Yinhan Xu, Haifeng CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease |
| title | CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease |
| title_full | CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease |
| title_fullStr | CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease |
| title_full_unstemmed | CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease |
| title_short | CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease |
| title_sort | crispr-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432308/ https://www.ncbi.nlm.nih.gov/pubmed/37600998 http://dx.doi.org/10.21037/hbsn-23-247 |
| work_keys_str_mv | AT wangyinhan crispreditedhepaticorganoidsasdrugscreeningplatformfornonalcoholicfattyliverdisease AT xuhaifeng crispreditedhepaticorganoidsasdrugscreeningplatformfornonalcoholicfattyliverdisease |